Related Experiment Video
Updated: Jul 11, 2025
Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
Published on: November 11, 2016
Emerging small molecule inhibitors of Bach1 as therapeutic agents: Rationale, recent advances, and future
Dmitry M Hushpulian1,2, Navneet Ammal Kaidery3,4, Debashis Dutta3,4
1Faculty of Biology and Biotechnologies, Higher School of Economics, Moscow, Russia.
Abstract:
The transcription factor Nrf2 is the master regulator of cellular stress response, facilitating the expression of cytoprotective genes, including those responsible for drug detoxification, immunomodulation, and iron metabolism. FDA-approved Nrf2 activators, Tecfidera and Skyclarys for patients with multiple sclerosis and Friedreich's ataxia, respectively, are non-specific alkylating agents exerting side effects. Nrf2 is under feedback regulation through its target gene, transcriptional repressor Bach1. Specifically, in Parkinson's disease and other neurodegenerative diseases with Bach1 dysregulation, excessive Bach1 accumulation interferes with Nrf2 activation. Bach1 is a heme sensor protein, which, upon heme binding, is targeted for proteasomal degradation, relieving the repression of Nrf2 target genes. Ideally, a combination of Nrf2 stabilization and Bach1 inhibition is necessary to achieve the full therapeutic benefits of Nrf2 activation. Here, we discuss recent advances and future perspectives in developing small molecule inhibitors of Bach1, highlighting the significance of the Bach1/Nrf2 signaling pathway as a promising neurotherapeutic strategy.
Insights
The transcription factor Nrf2 regulates cellular stress. Inhibiting Bach1, which represses Nrf2, alongside Nrf2 activation offers a promising neurotherapeutic strategy for diseases like Parkinson's.
Area of Science:
- Biochemistry
- Neuroscience
- Molecular Biology
Background:
- Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key regulator of cellular defense mechanisms.
- Current Nrf2 activators have limitations due to non-specific alkylating activity and side effects.
- Bach1, a transcriptional repressor and heme sensor, negatively regulates Nrf2 activity.
Purpose of the Study:
- To explore the therapeutic potential of targeting the Bach1/Nrf2 signaling pathway.
- To review advances in developing small molecule Bach1 inhibitors.
- To highlight the significance of this pathway for neurodegenerative diseases.
Main Methods:
- Literature review of Nrf2 and Bach1 functions.
- Analysis of Bach1's role in neurodegenerative disease pathogenesis.
- Discussion of small molecule inhibitor development for Bach1.
Main Results:
- Bach1 accumulation interferes with Nrf2 activation in neurodegenerative conditions.
- Bach1 degradation upon heme binding relieves Nrf2 repression.
- Combined Nrf2 stabilization and Bach1 inhibition may enhance therapeutic outcomes.
Conclusions:
- The Bach1/Nrf2 pathway presents a promising neurotherapeutic target.
- Developing specific Bach1 inhibitors is crucial for maximizing Nrf2's benefits.
- Targeting this pathway offers a novel strategy for neuroprotection.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:31The Intrinsic Apoptotic Pathway